IL24 and neoplasm: Alternatively, combining mda-7/IL-24 with a second therapeutic agent that may directly target the tumor, activate the immune system and/or affect the tumor microenvironment might promote a more sustained therapeutic response [7, 15-17, 24-26, 48, 56].